ArticlePharmaceutics2022

Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux.

Lucie Čermáková et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.